Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
2
Expiration
Dec 31, 2026
DTE
48d
Moneyness
ITM
Intrinsic
$4.01
IBRX 2 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | — | — | 0 | 15 |
| Nov 20, 2026 | 7d | $6.35 | -0.78% | 10 | 36 |
| Nov 27, 2026 | 14d | — | — | 0 | 21 |
| Dec 4, 2026 | 21d | — | — | 0 | 24 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | $6.30 | +0.00% | 2 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $6.35 | +2.42% | 2 | 1,346 |
| Mar 19, 2027 | 126d | $6.39 | +3.40% | 50 | 106 |
| Apr 16, 2027 | 154d | $8.40 | +0.00% | 20 | 15 |
| May 21, 2027 | 189d | $7.70 | +0.00% | 1 | 0 |
| Aug 20, 2027 | 280d | — | — | 0 | 0 |
| Nov 19, 2027 | 371d | — | — | 0 | 0 |
| Jan 21, 2028 | 434d | $6.00 | -6.25% | 2 | 5,401 |
| Mar 17, 2028 | 490d | $6.50 | -4.41% | 1 | 13 |
| Jan 19, 2029 | 798d | $6.76 | -2.73% | 16 | 88 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.